The linked FDA records identify Medtronic Vascular at 3576 Unocal Place, Santa Rosa, California, the address given in the premarket approval filings rather than a corporate headquarters. The applicant holds PMA P160043 for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System, product code NIQ, reviewed by the Cardiovascular advisory committee. The same PMA record also names the Onyx Frontier Zotarolimus-Eluting Coronary Stent System. Two linked PMA records appear in the supplied collection, one original approval and one 30-day notice. [1][2][7][8]

Original approval and device identity

PMA P160043 was approved on April 28, 2017, with a Federal Register notice date of May 2, 2017, and docket number 17M-2767. The approval statement describes the device as indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm. The generic name is coronary drug-eluting stent and the device class is 3. [2][8]

Medtronic's own product page describes the Resolute Onyx drug-eluting stent as used in complex percutaneous coronary intervention and lists continuous sinusoid technology with core wire technology, a BioLinx polymer and zotarolimus. The page also references a conformability comparison across 3.0 mm platforms and states that bench testing may not be indicative of clinical performance. [6]

Supplement activity

Supplement S096 was received September 17, 2026, and decided October 16, 2026, under decision code OK30, a 30-Day Notice. The supplement reason is a process change involving manufacturer, sterilizer, packager or supplier, and the applicant's own statement describes changing the point of finished device test sample collection. The expedited review flag is N. [1]

Earlier supplements appear in the supplied summaries. P160043/S034 was approved September 22, 2020, and P160043/S058 was approved September 15, 2022, with the latter summary also naming the Onyx Frontier Zotarolimus-Eluting Coronary Stent System. The S034 summary states that CDRH found the applicant's manufacturing facilities in compliance with the Quality System regulation at 21 CFR 820. [7][9]

Post-approval study and listing records

The original approval summary describes an ODE-led post-approval study involving continued follow-up of the RESOLUTE ONYX Core (2.25 mm–4.00 mm) clinical study, initiated prior to device approval. The FDA post-approval studies database page notes the agency's authority to require such studies. Post-approval requirements and restrictions are referenced to the approval order rather than restated in the summary. [5][7][8]

An establishment registration and device listing record exists for product code NIQ. The supplied PMA records list numerous FDA establishment identifiers and registration numbers associated with the filing, and the applicant address appears as 3576 Unocal Place, Santa Rosa, California 95403. [1][2][10]

What the collection shows

The supplied collection contains two linked PMA records, both under P160043: one approval and one 30-day notice. The smaller record sample likewise contains one approval and one 30-day notice. These counts describe the supplied filings as of the snapshot date and are not measures of total company portfolio, sales or safety performance. No recall records appear in the supplied sample. [1][2]